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Abstract 
Background: Emerging evidences have verified that long non-coding RNAs (lncRNAs) play important regulatory 
roles in the pathogenesis and progression of cancers. lncRNAs metastasis associated lung adenocarcinoma transcript 
1 (MALAT1) have been found to be up-regulated in some human cancers. The main objective of this study was to 
investigate the expression level and biological function of MALAT1 in gastric cancer (GC).
Methods: Quantificational real-time polymerase chain reaction (qRT-PCR) was performed to detect the mRNA levels 
of MALAT1 in 78 paired gastric carcinoma tissues and adjacent normal tissues, and the associations of MALAT1 expres-
sion with the clinicopathological features were analyzed, and the prognosis of gastric carcinoma patients was evalu-
ated. The HMGB2 mRNA and protein expressions were detected by qRT-PCR and western-blot analysis. Luciferase 
reporter assay was used to determine miR-1297 was a target of MALAT1.
Results: In this study, we demonstrated MALAT1 was up-regulation in GC tissues compared with adjacent normal 
tissues and higher MALAT1 expression was correlated with local invasion, lymph node metastasis and TNM stage. 
Patients with higher MALAT1 expression predicted a shorter survival and poor prognosis. Functionally, we revealed 
that MALAT1 promoted cells proliferation and invasion in GC. Mechanistically, our results demonstrated that MALAT1 
was negatively correlation with miR-1297 and functioned as a molecular sponging miR-1297, antagonizing its ability 
to suppress HMGB2 expression.
Conclusions: Taken together, these results demonstrated that MALAT1/miR-1297/HMGB2 axis acted as critical regu-
lator pathway in GC tumorigenesis and progression, which provided a novel therapeutic target for gastric cancer.
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Background
Gastric cancer is the most common form of gastrointes-
tinal cancer and a leading cause of cancer-related mortal-
ity worldwide [1]. Despite a marked decrease incidence, 
especially in mortality rate in many countries, the abso-
lute number of gastric cancer cases and deaths is still a big 
burden of the local health program [2]. Although some 
advancements in diagnostic and therapeutic including 
surgery, chemotherapy, and radiotherapy, due to the risk 
of relapse, distant metastasis, and chemoresistance, the 
5-year survival rate in GC patients remains larger unsat-
isfied [3]. Thus, to explore more molecular biomarkers 
for predicting responsiveness of treatment, tumor pro-
gression, and potential target therapies are becoming 
more urgent.
Long-non-coding RNA (LncRNAs), which are >200 nt 
in length, play important roles in diverse biological pro-
cesses, including cell proliferation, cell apoptosis, cell dif-
ferentiation, cell invasion, and metastasis by regulating 
gene expression at the epigenetic, transcriptional, and 
posttranscriptional levels [4]. Alterations in long non-
coding RNAs (lncRNAs) are associated with human car-
cinogenesis including gastric cancer. For instance, long 
non-coding RNA PVT1 indicated a poor prognosis of 
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gastric cancer and promoted cell proliferation through 
epigenetically regulating p15 and p16 [5]. Plasma level 
of H19 was significantly higher in GC patients and could 
serve as a potential biomarker for diagnosis of GC, in 
particular for early tumor screening [6]. MEG3 was 
decreased in GC patients and MEG3 could up-regulated 
Bcl-2 via its competing endogenous RNA (ceRNA) activ-
ity on miR-181a [7]. Long non-coding RNA HOXA-AS2 
promoted gastric cancer proliferation by epigenetically 
silencing P21/PLK3/DDIT3 expression [8]. These studies 
suggest an important role for MALAT1 in tumor biology.
Increasing evidences have shown that the aberrant 
expression of MALAT1 played a crucial role in carcino-
genesis [9]. Such as, previous studies suggested that long 
non-coding RNA MALAT1 promoted tumor growth and 
metastasis by inducing epithelial-mesenchymal transi-
tion in oral squamous cell carcinoma [10]. MALAT1 
increased AKAP-9 expression by promoting SRPK1-
catalyzed SRSF1 phosphorylation in colorectal cancer 
cells [11]. Wang et al. reported that MALAT1 promoted 
malignant development of esophageal squamous cell 
carcinoma by targeting β-catenin via Ezh2 [12]. In GC, 
Metastasis-associated long non-coding RNA drove 
gastric cancer development and promoted peritoneal 
metastasis and as a novel therapeutic target in patients 
with gastric neoplasia [13]. Qi and his assistants also 
confirmed that MALAT1 bound EZH2, suppressed the 
tumor suppressor PCDH10, and promotes gastric cellu-
lar migration and invasion [14]. However, the biological 
role of MALAT1 in GC and the underlying molecular 
mechanism still remain undefined.
In the study, our results demonstrated MALAT1 was 
up-regulation in GC tissues and patients with higher 
MALAT1 expression had a shorter survival and poor 
prognosis. Further experiments demonstrated that knock-
down of MALAT1 inhibited the GC cells proliferation and 
invasion. Mechanistically, we found that MALAT1 func-
tioned as a molecular sponge for miR-1297, antagonizing 
its ability to inhibit HMGB2 protein expression. To sum 
up, our findings revealed that MALAT1 might function as 
a competing endogenous RNA (ceRNA) sponge for miR-
1297 modulating HMGB2 expression. The MALAT1/
miR-1297/HMGB2 regulator pathway provided a novel 
therapeutic method for gastric cancer.
Methods
Patients and tissue samples
Human GC tissues and adjacent non-cancerous tissues 
were collected from 78 GC patients who underwent 
surgical resection and obtained from Hebei Cangzhou 
Central Hospital. The diagnosis of all GC patients was 
histopathologically confirmed by two professional pathol-
ogists. None of the patients had received radiotherapy or 
chemotherapy before surgery. Written informed consent 
was obtained from all patients or their families for their 
related tissues were used. The approval for this study was 
obtained from Research Ethics Board at Hebei Cangzhou 
Central Hospital.
Cell culture
The human GC cell lines MKN45, MKN28, BGC-823, 
and SGC-7901 and an immortalized normal gastric 
epithelial cell line GES-1 were purchased from the Cell 
Bank of the Chinese Academy of science. All cells were 
cultured in RPMI 1640 medium (GIBCO, Carlsbad, CA) 
with 10% FBS and 5% CO2 at 37 °C.
QRT‑PCR analysis
Total RNA from tissues and GC cells was extracted using 
Trizol reagent (Invitrogen, Carlsbad, USA). The One Step 
SYBR® Prime Script® PLUS RT-RNA PCR Kit (TaKaRa, 
Dalian, China) was used for the Real-Time PCR analysis. 
All experiments were repeated three times. GAPDH or 
U6 was used as the endogenous control. The relative fold 
changes in the transcripts were calculated using the 2−ΔΔCt 
method. The QRT-PCR was performed at 95  °C for 15  s, 
followed by 40 cycles of 95  °C for 5  s and 60  °C for 34  s 
at ABI7500 real-time PCR detection system. The primer 
sequences used were as follows: for GAPDH-forward, 
5′-GTCAACGGATTTGGTCTGTATT-3′andGAPDH-
reverse, 5′-AGTCTTCTGGGTGGCAGTGAT-3′; MALAT1-
for ward5 ′-ATGCGAGTTGTTCTCCGTCT-3 ′and 
MALAT1-reverse, 5′-TATCTGCGGTTTCCTCAAGC-3′.
Cell transfection assays
Cell transfections were performed using the Lipo-
fectamine 3000 kit (Invitrogen) according to the manu-
facturer’s instructions. To knockdown MALAT1, the two 
siRNA oligonucleotides targeting MALAT1 and negative 
control were purchased from GenePharma (Shanghai, 
China) and were transfected into GC cells. The sequences 




sense-2, 5′-AUAAAUCCCUUUACACCUCTT-3′). The 
working concentration of relative plasimids was 100 nM. 
MiR-1297 plasmid was transfected into GC cells using 
Lipofectamine TM 3000 (Invitrogen, Carlsbad, CA, 
USA).
Cell proliferation and invasion assays
Cell proliferation was measured using the Cell Counting 
Kit-8 (CCK-8). Briefly, 3000 MKN45 or MKN28 cells/
well were seeded into a 96-well plate. At daily intervals 
of 0, 24, 48, and 72 h, the optical density was measured 
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at 450 nm using a microtiter plate reader (Quant BioTek 
Instruments). The cell invasion assays was performed 
according to the previously described using Transwell 
Chamber Cell Culture (8-μm pore membrane, BD Bio-
sciences) [15]. The 1  ×  105 cells GC cells were added 
to the top chamber of 24-well plates with serum-free 
medium. The bottom chamber was added medium with 
10% FBS. Cells in chamber were fixed with methanol for 
20 min and then staining with Crystal violet for 10 min. 
Invaded cells were finally observed under a microscope 
and the number was counted. The results represent the 
average of three replicates.
Western blotting assays
Cells were lysed in RIPA buffer containing fresh protease 
and phosphatase inhibitor cocktails (Sigma). Protein 
was separated by 10% SDS–PAGE and was transferred 
to PVDF membranes. The membranes were blocked 
in 5% skim milk and incubated with anti-HMGB2 anti-
body (1:1000 dilution, CST, USA), anti-PCNA antibody 
(1:3000 dilution, Abcam, CST, USA), anti-Ki67 antibody 
(1:1000 dilution, CST, USA) and anti-GAPDH antibody 
(1:2000 dilution, CST, USA) and incubated overnight at 
4 °C. GAPDH served as an endogenous control and incu-
bated overnight at 4  °C. Then, Horseradish peroxidase 
(HRP)-conjugated secondary antibody (1:1000 dilution, 
Abcam, USA) was incubated at room temperature for 
2 h. Blots were developed using enhanced chemilumines-
cence detection reagents and scanned with a Molecular 
Imager system (Bio-Rad). Three repeated experiments 
were performed.
Luciferase reporter assay
PMIRGLO-MALAT1 wild type (WT) or pMIRGLO-
MALAT1 mutant type (MUT) reporter plasmid was 
co-transfected with miR-1297 mimic or NC mimic into 
MKN45 cells. Reporter plasmid and the internal con-
trol renilla luciferase plasmid were carried out with the 
appropriate plasmids using lipofectamine 3000 (Invitro-
gen, USA). The relative luciferase activity was normalized 
to renilla luciferase activity after transfection at 48 h, and 
luciferase activity was measured using a dual-luciferase 
reporter gene assay system (Promega, Madison, USA). 
Moreover, full-length MALAT1 by PCR was constructed 
and were transfected with a luciferase reporter vector 
containing perfect miR-1297 binding site (Sensor) wild 
type (WT) or mutant type (MUT) into theBCG-823 cells 
that expressed lower MALAT1 levels.
Statistical analyses
All statistical analysis was performed using SPSS 16.0 
software (version 16.0; Chicago, IL). Data are presented 
as mean  ±  standard deviation. Student’s t tests were 
used to evaluate significant differences between any two 
groups of data. One-way analysis of variance (ANOVA) 
was performed to analyze the differences between 
groups. Kaplan–Meier method and compared by log-
rank test were used to construct survival curves. Pearson 
correlation analysis was used to detect the significance of 
association between MALAT1 and miR-1297 expression. 
The P < 0.05 was considered statistically significant.
Results
Expression of MALAT1 in gastric cancer tissues and cells
To investigate the MALAT1 expression in 78 paired 
GC tissues and adjacent non-cancer tissues, qRT-PCR 
analysis was applied. The results demonstrated that the 
expression of MALAT1 in GC tissues was up-regulated 
compared to the paired adjacent non-cancer tissues 
(Fig.  1a). We then analyzed the correlation between 
MALAT1 and Clinicopathological factors. As shown 
in Table  1, the result showed that MALAT1 expres-
sion was significantly correlation with local invasion, 
lymph node metastasis and TNM stage. Furthermore, 
we demonstrated that patients with higher MALAT1 
expression had a shorter survival time in GC patients 
(Log-rank  =  23.94, P  <  0.001, Fig.  1b). As shown in 
Fig. 1c, we also demonstrated that MALAT1 expression 
was also significantly higher in four cell lines compared 
with that in GES-1 cells. The siRNA-2 was used to per-
form to silence the MALAT1 expression in the follow-
ing experiences, according to knockout efficiency in the 
MKN45 and MKN28 cells (Fig. 1d, e).
MiR‑1297 is a direct target of MALAT1
Recently, accumulating reports had indicated that 
MALAT1 functioned as ceRNAs to indirectly regulate 
miRNAs and hence functionally liberate other RNA tran-
scripts [16]. To detect whether MALAT1 has a similar 
mechanism in GC cells, the online predicted bioinfor-
matics software starbase (http://starbase.sysu.edu.cn/) 
was used to predict the potential mircroRNA binding 
sites in MALAT1. We found that miR-1297 had a bind-
ing site in MALAT1 (Fig.  2a). To further explore the 
potential correlation between MALAT1 and miR-1297, 
we examined the expression level of miR-1297 in GC tis-
sues. Compared to the normal tissues, the expression of 
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miR-1297 was markedly downregulated in GC tissues 
and cells (Fig.  2b, c). Furthermore,Pearson correlation 
analysis confirmed that MALAT1 expression level was 
negatively related to miR-1297 expression level in GC tis-
sues (r = −0.317, P  <  0.05, Fig.  2d). Next, we explored 
the expression of miR-1297 when MALAT1 was knocked 
down in MKN45 and MKN28 cells, and results demon-
strated knockdown MALAT1 expression caused a sig-
nificantly increase of miR-1297 expression (Fig.  2e). On 
the other hand, MALAT1 was significantly inhibited 
by transfecting the miR-1297 plasmid into MKN45 and 
MKN28 cells (Fig. 2f ).
To confirm the direct binding relationship between 
MALAT1 and miR-1297, a luciferase activity assay 
was performed. The predicted miR-1297 binding site 
(MALAT1-WT) and its mutant type (MALAT1-MUT) 
were amplified and directly fused to the downstream 
of the luciferase reporter gene in the PMIRGLO-basic 
vector (Fig.  2a). The results showed that co-transfetion 
of miR-1297 and PMIRGLO-MALAT1-WT significantly 
decreased the luciferase activity, whereas co-transfec-
tion of miR-NC and PMIRGLO-MALAT1-MUT did 
not change the luciferace activity (Fig.  2g). Moreover, 
transfect with a luciferase reporter vector containing 
miR-1297 binding site-WT into the BCG-823 cells that 
expressed lower MALAT1 levels together with increas-
ing amounts of a plasmid that expressed MALAT1 inhib-
ited the miR-1297 binding site-WT luciferace activity 
(Fig.  2h). These results demonstrated that there exist a 
negative regulation between MALAT1 and miR-1297.
MALAT1 regulates miR‑1297 to modulate HMGB2 in gastric 
cancer cells
A previous study found that miR-1297 promoted apopto-
sis and inhibited the proliferation and invasion of hepa-
tocellular carcinoma cells by targeting HMGA2 [17]. 
Fig. 1 Up-regulation of MALAT1 in tumor tissues samples and cell lines. a The MALAT1 expression in 78 pairs of gastric cancer and corresponding 
non-cancerous gastric tissues was detected by qRT-PCR assays. **P < 0.05, the internal control was GAPDH. b Kaplan–Meier survival curve and log-
rank test was perform to analyze the correlation between MALAT1 expression and the over survival (OS) time. c The MALAT1 expression in gastric 
cancer cells and an immortalized normal gastric epithelial cell line GES-1 was detected by qRT-PCR assays. **P < 0.05. d, e The MALAT1 expression 
in MKN45 or MKN28 cells was detected after knockdown of MALAT1 by qRT-PCR assays. Results were represented as the average ± SD based on 3 
independent experiments. **P < 0.05
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Thus, based on above result, we also investigated whether 
MALAT1 could regulate the expression of the miR-1297 
targeting HMGB2. The results demonstrated that the 
mRNA and protein levels of HMGB2 were significantly 
decreased after knockdown of MALAT1 and was upreg-
ulated by miR-1297 inhibitor in the MKN45 cells, and 
the reduced expression of HMGB2 when knockdown of 
MALAT1 could be restored by co-transfecting with si-
MALAT1 and miR-1297 inhibitor (Fig.  3a, b). Moreo-
ver, we also found that the mRNA and protein levels of 
HMGB2 were remarkably decreased after knockdown of 
MALAT1 in the MKN 28 cells,and this reduction could 
be restored by co-transfecting with si-MALAT1 and 
miR-1297 inhibitor (Fig.  3c, d). Our results confirmed 
that MALAT1 promoted HMGB2 through negatively 
regulating miR-1297.
MALAT1 regulates miR‑1297 to promote gastric cancer cell 
proliferation and invasion
Next, we examined MALAT1 effects on GC cell growth. 
CCK8 assays revealed that knockdown of significantly 
reduced the MKN45 and MKN28 cell proliferation abili-
ties, and this reduction could be restored by co-transfect-
ing with si-MALAT1 and miR-1297 inhibitor (Fig. 4a, b). 
In addition, transwell cell invasion assay also revealed 
that knockdown of MALAT1 efficiency inhibited the 
cell invasion abilities in MKN45 or MKN28 cells, and 
this inhibition could be restored by co-transfecting with 
si-MALAT1 and miR-1297 inhibitor (Fig. 4c, f ). We fur-
ther identified the underlying effects of HMGB2 on GC 
cell proliferation. CCK8 cell proliferation was performed 
to detect the cell growth abilities after HMGB2 silencing. 
The results showed that cell proliferation abilities were 
inhibited after HMGB2 silencing in MKN45 cell (Fig. 5a). 
Moreover, the expression of Proliferating Cell Nuclear 
Antigens (PCNA) and Ki-67 were inhibited after HMGB2 
silencing in MKN45 cell (Fig. 5b, c). Therefore, the results 
demonstrated that MALAT1 negatively regulated miR-
1297 and promote the HMGB2 expression in gastric can-
cer progression.
Discussion
Recent research has revealed that MALAT1 play pivotal 
roles in tumorigenesis of cancers including gastric cancer 
[16, 18, 19]. MALAT1 was aberrantly highly expressed 
in GC cell lines and promoted cell proliferation in gas-
tric cancer by recruiting SF2/ASF [20]. Plasma MALAT1 
levels were significantly higher in gastric cancer patients 
with distant metastasis than patients without distant 
metastasis and the healthy controls [21]. In the study, 
we found the expression level of MALAT1 was signifi-
cantly higher in gastric cancer tissues compared with 
adjacent normal tissues. Higher expression of MALAT1 
was positively associated with local invasion, lymph node 
invasion and TNM stage. In addition, overexpression of 
MALAT1 was associated with short survival time. These 
results implicated that MALAT1 may play an important 
role in gastric cancer progression.
Previous reports have revealed that competing endog-
enous RNA (ceRNA) regulator mechanisms involved in 
MALAT1. For example, knockdown of long non-cod-
ing RNA MALAT1 increases the blood-tumor barrier 
permeability by up-regulating miR-140 [22]. MALAT1 
induced migration and invasion of human breast can-
cer cells by competitively binding miR-1 with cdc42 
[23]. Wang et  al. reported that long non-coding RNA 
Table 1 Association between  MALAT1 expression levels 














 Male 42 24 18
 Female 36 16 20
Age (years) 0.621
 ≤50 45 22 23
 >50 33 18 15
Histological grade 0.879
 High 19 9 10
 Middle 24 12 12
 Low 35 19 16
Local invasion 0.003**
 T1, T2 34 24 10
 T3, T4 44 16 28
Lymph node metastasis 0.043**
 No 43 27 18
 Yes 35 13 22
Distant metastasis 0.086
 No 50 22 28
 Yes 28 18 10
TNM stage 0.039**
 I/II 36 23 13
 III/IV 42 17 25
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MALAT1 promoted gallbladder cancer cell prolifera-
tion and invasion targeting ANXA2 and KRAS by act-
ing as a molecular sponge to regulate miR-206 [24]. 
Another study in lung adenocarcinoma demonstrated 
that lncRNA MALAT1 exerted oncogenic functions by 
targeting miR-204 [25]. It also been verified MALAT1 
functioned as a competing endogenous RNA to regulate 
ZEB2 expression by sponging miR-200s in clear cell kid-
ney carcinoma and promoted cell invasion and metasta-
sis [26]. According to luciferase reporter assays results, 
co-transfection of miR-1297 and PMIRGLO- MALAT1-
WT significantly decreased the luciferase activity. In vitro 
Fig. 2 MALAT1 directly targeted miR-1297 in GC cells. a Bioinformatic analysis identified a potential miR-1297 target site of MALAT1 by software 
starbase (http://starbase.sysu.edu.cn/). b The miR-1297 expression levels in 78 pairs of gastric cancer and corresponding non-cancerous gastric 
tissues was detected by qRT-PCR assays. **P < 0.05, the internal control was U6, Student’s t test. c The miR-1297 expression in gastric cancer cells 
and an immortalized normal gastric epithelial cell line GES-1 was detected by qRT-PCR assays, the internal control was U6, **P < 0.05. d Pearson 
correlation analysis was used to detect the significance of association between MALAT1 and miR-1297 expression. e The miR-1297 expression in 
MKN45 and MKN28 cells was detected after MALAT1 silencing by qRT-PCR assays, the internal control was U6, **P < 0.05. f The MALAT1 expression 
in MKN45 or MKN28 cells was detected after transfecting miR-1297 by qRT-PCR assays, the internal control was GAPDH, **P < 0.05. g Co-transfection 
of miR-1297 mimic and PMIRGLO-MALAT1-WT strongly decreased the luciferase activity, while co-transfection of miR-1297 mimic and PMIRGLO-
MALAT1-MUT and NC group did not change the luciferase activity, h Co-transfection of PmiRGLO-miR-1297-WT and MALAT1 overexpressed plasmid 
strongly decreased the luciferase activity, while co-transfection of PMIRGLO-miR-1297-MUT and MALAT1 overexpressed plasmid did not change the 
luciferase activity, Results were represented as the average ± SD based on 3 independent experiments. **P < 0.05
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studies further confirmed that MALAT1 negatively regu-
lated miR-1297 expression levels, which promoted cell 
proliferation and cell invasion. Moreover, miR-1297 was 
up-regulated after MALAT1 silencing, notably, ectopic 
expression of miR-1297 increased the MALAT1 expres-
sion levels. These findings demonstrated that there exist 
a negative regulation between MALAT1 and miR-1297.
Overexpression of high-mobility group box  2 was 
associated with tumor aggressiveness and prognosis of 
hepatocellular carcinoma [27]. Knockdown of HMGB2 
decreased the chemoresistance of gastric cancer cells 
[28]. Our results showed that cell proliferation abilities 
were inhibited and PCNA and Ki-67 expression were 
reduced after HMGB2 silencing in MKN45 cell. Previous 
study showed that miR-1297 inducing HCC cell apop-
tosis and inhibited cell the proliferation and invasion 
by targeting HMGB2 [17]. In our study, knockdown of 
MALAT1 was able to reduce the mRNA and protein lev-
els of HMGA2 and miR-1297 inhibitor could enhanced 
the HMGB2 expression. What’s more, knockdown of 
MALAT1 could reduce the mRNA and protein levels of 
HMGA2 which was dismissed by miR-1297 inhibitor. 
These data revealed that MALAT1 exerts its biological 
effects at least in part by modulating HMGA2 expression.
Fig. 3 MALAT1 regulated miR-1297 to modulate HMGB2 in gastric cancer cells. a, b The mRNA and protein expression of HMGB2 after transfecting 
si-NC, si-MALAT1, si-MALAT1 and miR-1297 inhibitor in MKN45 cells was detected by qRT-PCR assays and western-blotting analysis, **P < 0.05. c, d 
The mRNA and protein expression of HMGB2 after transfecting si-NC, si-MALAT1, si-MALAT1 and miR-1297 inhibitor in MKN28 cells was detected by 
qRT-PCR assays and western-blotting analysis. Results were represented as the average ± SD based on 3 independent experiments. **P < 0.05
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Fig. 4 MALAT1 regulated miR-1297 expression and promoted gastric cancer cell proliferation and invasion. a, b CCK8 cell proliferation was 
performed to detect the cell abilities after MALAT1 down-regulation, and was rescued by miR-1297 inhibitor treatment in MKN45 or MKN28 cells, 
**P < 0.05. n.s. not statistics significant. c–f Transwell cell invasion assays and analysis were performed to detect the cell abilities after MALAT1 
down-regulation, and were rescued by miR-1297 inhibitor treatment in MKN45 or MKN28 cells, **P < 0.05. n.s. not statistics significant. Results were 
represented as the average ± SD based on 3 independent experiments
Fig. 5 Knockdown of HGMB2 inhibited the GC cell proliferation. a CCK8 cell proliferation was performed to detect the cell abilities after HMGB2 
down-regulation in MKN45 cells. b The protein expression of PCNA and Ki-57 was determined by western-blotting analysis in MKN45 cells. 
**P < 0.05, the results were represented as the average ± SD based on 3 independent experiments
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Conclusions
In conclusion, we demonstrated that MALAT1 was sig-
nificantly overexpressed in gastric cancer tissues and 
cell lines and revealed a MALAT1/miR-1297/HMGB2 
regulator pathway in GC. Thus, our results indicated that 
intervention of MALAT1/miR-1297/HMGB2 regulator 
pathway could inhibit gastric cancer progression.
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